Navigation Links
Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
Date:4/16/2008

d enhance its attractiveness to potential oncology partners."

Data on Kosan's third-generation Hsp90 inhibitors were presented in two posters at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held in San Diego, CA.

Abstract 5636, "Correlation between In Vitro and In Vivo Activities of Hsp90 Inhibitors," presented data showing the KOS-2484, Kosan's lead non-benzoquinone ansamycin, has demonstrated the tightest binding affinity for Hsp90 reported to date, accumulates in tumor cells and has superior retention properties leading to a long lifetime in tumor tissue. These properties of KOS-2484 result in this molecule showing pronounced efficacy in multiple preclinical tumor models.

Abstract 5630, "Anti-Tumor Activity of Non-Benzoquinone Ansamycin Hsp90 Inhibitors in Murine Xenograft Models," presented data showing that KOS-2484 induces tumor regression at well-tolerated doses in xenograft models of both liquid and solid tumors, including acute myelogenous leukemia (AML), multiple myeloma and colon cancer models. Most notably, KOS-2484 demonstrated almost complete regression of very large (1000 mm3) AML xenografts when dosed on an infrequent (twice a week) schedule. KOS-2484 also prolongs survival in a mouse orthotopic model of AML. These findings underscore that KOS-2484, Kosan's lead non-benzoquinone ansamycin Hsp90 inhibitor, has significant potential as a novel anticancer agent.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive me
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
2. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
3. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
4. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
5. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
6. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
7. Kosan Announces February 28, 2008 Conference Call and Webcast
8. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
9. Kosan Announces Third Quarter 2007 Financial Results
10. Kosan to Reacquire Epothilone Program From Roche
11. Kosan Biosciences to Host Research & Development Day on October 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that ... that it has completed its previously announced private placement ... of 5,000,000 shares of common stock and five-year warrants ... for aggregate gross proceeds of $2.5 million.   ...
... June 23, 2011 ,   ... science consulting,has published an insight into the future development ... out a,vision of how the industry may look as ... reflects on the decisions it has made.,In particular, Alacrita ...
... June 22, 2011 Wound Management Technologies, Inc., (OTCQB: ... solutions today announced that Company President Deborah Jenkins Hutchinson, ... OneMedForum NY Conference on Thursday, June 23, 2011 at ... 45 East 45 St. in New York City. The ...
Cached Biology Technology:Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 2Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 3Alacrita Asks "Are We All Biotech Now?" 2Alacrita Asks "Are We All Biotech Now?" 3Wound Management Technologies' Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT 2Wound Management Technologies' Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT 3
(Date:7/10/2014)... partners predict that western Lake Erie will have a ... the 2014 bloom season in late summer. However, the ... year,s intense bloom, and considerably less than the record-setting ... lake,s western basin and are classified by an estimate ... , Harmful algal blooms (HABs) were common in ...
(Date:7/10/2014)... Clarksburg, MDBrightFocus Foundation, a nonprofit organization funding cutting-edge, ... diseases of glaucoma and macular degeneration, today announced ... to 55 scientists in 19 U.S. states, the ... http://www.brightfocus.org/Grants2014 . , With these latest ... million in research funding in 2014. , The ...
(Date:7/10/2014)... collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... spot, which appears as a red mark, is an ... recognized temperatures higher than background. When accompanied by plumes ... are diagnostic for fire. , This area of ... from the fires, although the smoke released by any ...
Breaking Biology News(10 mins):NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 3BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3
... University of Leicester and part-funded by The Leverhulme Trust aims ... By bringing together an artist and a neuroscientist, both ... perception. In the process of the research, both artist and ... the eye of the beholder. Rodrigo Quian Quiroga, Neuroscientist ...
... opinion that inflammation in adipose tissue may cause insulin resistance, ... Swedish medical university Karolinska Institutet, published in the New ... in the body fat is only pernicious. Instead the findings ... necessary for fat cell turnover in the lean, healthy state. ...
... not just thinking big but also very, very, very ... director of Binghamton University,s Center for Advanced Sensors and ... that would detect and identify engineered nanoparticles. Her research ... the environmental release and transformation of these particles. ...
Cached Biology News:Beauty is in the eye of the beholder? 2Inflammation in body fat is not only pernicious 2Chemist monitors nanotechnology's environmental impact 2
...
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
Biology Products: